tradmap

PMCB PharmaCyte Biotech, Inc.

$0.75 -3.93%

Healthcare · Biological Products, (No Diagnostic Substances)

PharmaCyte Biotech, Inc. (PMCB) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $8 million. Shares last traded at $0.75, 50.1% below their 52-week high. Over the past year the stock is down 32.0%. PMCB trades at a price-to-earnings ratio of 0.26, below the Biological Products, (No Diagnostic Substances) median of 22.74.

Market Cap
$8M
Shares Out
10.7M
EPS (TTM)
$-4.44
P/E Ratio
0.26
P/S Ratio
P/B Ratio
0.21
Dividend / Share
Dividend Yield
52-Week High
$1.50
52-Week Low
$0.61
Volume
6,367
Avg Vol (3m)
3,230.016

Performance

1W
-0.58%
1M
+0.90%
3M
+3.63%
6M
-19.69%
YTD
+1.93%
1Y
-32.02%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
48.17
SMA (50)
$0.76
SMA (200)
$0.83
Price vs SMA50
-1.29%
Price vs SMA200
-9.81%
ATR (14)
$0.04

Financials

Revenue
$0M
Net Income
$31M
Gross Margin
Operating Margin
Net Margin
Return on Equity
80.4%
Return on Assets
54.9%
Current Ratio
12.33
Debt / Equity
0.01
Revenue Growth (YoY)

Latest reported annual period ending 2025-04-30 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 $-2.41 2026-03-17
Q2 2026 $-2.47 2025-12-18
Q1 2026 $-1.23 2025-09-15
FY 2025 $3.19 2025-08-11
Q3 2026 $1.67 2026-03-17
Q2 2026 $1.83 2025-12-18

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

PMCB vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/E vs peers
0.26 / 22.74 med
-99% discount
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.